Author Information
Glenn M. Chertow is a prominent researcher affiliated with Stanford University, Stanford, CA. His research primarily focuses on kidney disease, chronic kidney conditions, and their management. His work has significantly contributed to the understanding and treatment of kidney-related health issues, with a particular emphasis on innovative treatment methods and clinical genetics in chronic kidney disease (CKD).Research Contributions
Glenn M. Chertow has made substantial contributions to the field of nephrology, as evidenced by his numerous publications in prestigious journals. In 2022 alone, he has authored several important papers, including studies on the cost-effectiveness of dapagliflozin for non-diabetic chronic kidney disease, the use of SARS-CoV-2 neutralizing monoclonal antibodies in kidney transplant recipients, and the cardiovascular outcomes related to sodium-glucose co-transporter-2 inhibitors. His research also explores the intersection of diabetes, cardiovascular health, and kidney disease, and he has been a part of significant clinical trials aimed at improving kidney care, such as the CALCIPHYX study.Aliases
Throughout his academic career, Glenn M. Chertow has published under various aliases, including Glenn Matthew Chertow, G M Chertow, Glennm. Chertow, Glen Chertow, and several others. These variations are common in academic publishing and reflect different citation formats across journals and institutions.Publication and Citation Metrics
| Metric |
Value |
| Total Citation Count |
85,641 |
| h-index |
132 |
| Total Paper Count |
886 |
